BioLargo’s business strategy is to harness and deliver Nature’s Best Solution® — free-iodine — in a safe, efficient, environmentally sensitive and cost-effective manner. Its proprietary technology works by combining micro-nutrient salts with liquid from any source to deliver free-iodine on demand, in controlled dosages, in order to balance efficacy of performance with concerns about toxicity. The technology has potential commercial applications within global industries, including but not limited to oil and gas, animal health, beach and soil environmental uses, consumer products, agriculture, food processing, medical, and water. It features solutions for odor & moisture control, disinfection and contaminated water treatment. The company’s goal is to improve the quality of life for people worldwide, while it protects the environment, and produces positive economic results for our customers, partners, and shareholders. Its website is www.BioLargo.com. Its Odor-No-More® product was awarded two Editor’s Choice Awards, including a “Product of the Year” award, by the Horse Journal, a top industry publication, as well as a Best New Product SuperZoo Award, and are sold by BioLargo’s wholly owned subsidiary, Odor-No-More, Inc. (www.OdorNoMore.com). BioLargo also owns a 50% interest in the Isan System, already commercialized in Australia, which was honored with a Top 50 Water Company for the 21st Century award by the Artemis Project. In early 2011, the company signed an exclusive license agreement for use in pet products with industry leader Central Garden and Pet.
BioLargo (BLGO) Stock Quote and News:
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the 
0 comments
Add your comment
Commenting is allowed only for registered users.